Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10714043 | 0.95 | GAA (0.54) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| SCHEMBL886919 | 0.89 | GLA (0.56) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| SCHEMBL39610 | 0.84 | GLA (0.55) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| SCHEMBL1358701 | 0.83 | KDM4E (0.61) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| Hydrochloric Acid SCHEMBL11543248 | 0.82 | GLA (0.60) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| SCHEMBL3362202 | 0.79 | ARG1 (0.38) | GAASMN1; SMN2KEAP1PAOXMAPK1 | |
| SCHEMBL2328827 | 0.78 | KDM4E (0.64) | GAAGLASMN1; SMN2KDM4ELMNA | |
| SCHEMBL8616993 | 0.78 | KDM4E (0.59) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| SCHEMBL5843494 | 0.77 | KDM4E (0.57) | GAAGLASMN1; SMN2KEAP1KDM4E | |
| SCHEMBL1726737 | 0.77 | KDM4E (0.57) | GAAGLASMN1; SMN2KEAP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735082-A1 | MATERIALS, METHODS, AND SYSTEMS FOR SEPARATING AND IDENTIFYING PROTEINS FROM MIXTURES | Ciphergen Biosystems, Inc. (US) | 2006-12-27 | — | — | EP | claimed |
| US-20050227001-A1 | Materials, methods and systems for separating and identifying proteins from mixtures | CIPHERGEN BIOSYSTEMS INC. | 2005-10-13 | — | — | US | claimed |
| WO-2005089911-A1 | MATERIALS, METHODS, AND SYSTEMS FOR SEPARATING AND IDENTIFYING PROTEINS FROM MIXTURES | CIPHERGEN BIOSYSTEMS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| WO-2005054548-A2 | METHODS, COMPOSITIONS, AND KITS FOR PROTEIN CRYSTALLIZATION | INVITROGEN CORPORATION (US) | 2005-06-16 | — | — | WO | claimed |
| EP-0425590-B1 | PROCESS FOR STABILISING THE pH OF AQUEOUS FEED SOLUTIONS AND FOR ABSORBING AND BUFFERING URINE AND WOUND SECRETIONS | MARIGEN SA (CH) | 1993-12-15 | — | — | EP | claimed |
| EP-0425590-A1 | PROCESS FOR STABILISING THE pH OF AQUEOUS FEED SOLUTIONS AND FOR ABSORBING AND BUFFERING URINE AND WOUND SECRETIONS. | MARIGEN SA (CH) | 1991-05-08 | — | — | EP | claimed |
| WO-1990011348-A1 | PROCESS FOR STABILISING THE pH OF AQUEOUS FEED SOLUTIONS AND FOR ABSORBING AND BUFFERING URINE AND WOUND SECRETIONS | MARIGEN S.A. (CH) | 1990-10-04 | — | — | WO | claimed |
| EP-4125813-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY | Kiora Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20210299039-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY | EYEGATE PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021195016-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASE BY CONTACT LENS MEDIATED DRUG DELIVERY | EYEGATE PHARMACEUTICALS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-1888213-B1 | FLUIDICS DEVICE | BIO RAD LABORATORIES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20130319863-A1 | METHODS, COMPOSITIONS, AND KITS FOR PROTEIN CRYSTALLIZATION | Life Technologies Corporation (US) | 2013-12-05 | — | — | US | disclosed |
| US-8491791-B2 | Fluidics device | BIO-RAD LABORATORIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-0417588-B1 | PROCESS FOR THE PREPARATION OF A COMPLEXED DRUG | RÖHM GMBH (DE) | 1992-08-19 | — | — | EP | disclosed |
| EP-0485840-A2 | Pharmaceutical oral composition and coating agent containing a polysaccharide degradable in the colon | RÖHM GMBH (DE) | 1992-05-20 | — | — | EP | disclosed |
| EP-0425590-A1 | PROCESS FOR STABILISING THE pH OF AQUEOUS FEED SOLUTIONS AND FOR ABSORBING AND BUFFERING URINE AND WOUND SECRETIONS. | MARIGEN SA (CH) | 1991-05-08 | — | — | EP | disclosed |
| EP-0417570-A1 | Aqueous polyacrylat-dispersion as hot-melting adhesive | RÖHM GMBH (DE) | 1991-03-20 | — | — | EP | disclosed |
| EP-0417588-A2 | Process for the preparation of a complexed drug | RÖHM GMBH (DE) | 1991-03-20 | — | — | EP | disclosed |
| WO-1990011348-A1 | PROCESS FOR STABILISING THE pH OF AQUEOUS FEED SOLUTIONS AND FOR ABSORBING AND BUFFERING URINE AND WOUND SECRETIONS | MARIGEN S.A. (CH) | 1990-10-04 | — | — | WO | disclosed |
| EP-0376094-A2 | Process for hardening an injection agent | RÖHM GMBH (DE) | 1990-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130319863-A1 | METHODS, COMPOSITIONS, AND KITS FOR PROTEIN CRYSTALLIZATION | CHLSN, CPN1, CRYAA | GAA 1753/4885GLA 580/4885SMN1; SMN2 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.